We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
MET is a 125k bp proto-oncogene receptor tyrosine kinase, known also as c-MET or hepatocyte growth factor receptor (HGFR). It has embryonic activity in epithelial cells, playing a role in the development of a variety of tissues and organs. In adults, MET expression is seen only in stem and progenitor cells. Mutation of MET is associated with a poor prognosis as it can trigger tumor growth, angiogenesis and metastasis. MET amplification has been observed in both non-small cell lung carcinomas (NSCLCs) and esophageal adenocarcinomas. The presence of MET amplification is associated with acquired resistance to certain tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib and sensitivity to other TKIs such as crizotinib. This FISH assay has been validated in both specimen types for detection of MET amplification.
Disease State: Mesothelioma vs. Adenocarcinoma
CPT Code(s): 88374. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
• Formalin-fixed, paraffin-embedded tissue block or cell block - OR - • Minimum of 5 unstained slide cut at 4µm for each test requested